NSE: SYNGENE | BSE: 539268

Expensive Performer

Download real time

698.40 15.60 (2.28%)

27.30% Fall from 52W High

317.6K NSE+BSE Volume

NSE 19 Mar, 2025 11:36 AM (IST)

28,113.2

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Syngene International Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SYNGENE, BSE:539268 Syngene International Ltd.

Syngene International Ltd.

05 Jan 2021

698.40

2.28%

Syngene Ltd - A Behemoth in the making

Syngene International Ltd.

Monarch Networth Capital Limited

Long standing multi-year client relationships with 25% of 360+ clients associated with Syngene for more than 5 years. Capex ramp up in core business (Discovery, Development, RnD) to...

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

23 Oct 2020

698.40

2.28%

Syngene Intl

Buy: Syngene International Ltd.

Dolat Capital

Number of FII/FPI investors increased from 337 to 359 in Dec 2024 qtr.

Syngene International Ltd.

23 Oct 2020

698.40

2.28%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Syngene International Ltd. is trading below its 50 day SMA of 743.5

Syngene International Ltd.

23 Jul 2020

698.40

2.28%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Revenues grew at ~16% CAGR in FY16-20 to | 2012 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It has a pool...

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

14 May 2020

698.40

2.28%

Syngene International Ltd

Buy: Syngene International Ltd.

Target

ICICI Securities Limited

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

24 Jan 2020

698.40

2.28%

Biologics/Small molecules progressing well; Research Services growth moderate

Neutral: Syngene International Ltd.

Motilal Oswal

In addition to CRAMS (Syngene)/Biosimilars, BIOS is building another lever i.e. Small molecules for growth over the next 4-5 years. Revenue increased 13% YoY to INR17.5b (in-line) in 3QFY20, mainly led by strong growth in Biologics (+31% YoY; 34% of sales) and Small Molecules Research Services (30% of sales) grew 11% YoY to INR5.2b. Aspart BLA is likely to Gross margin is likely to improve in the coming quarters with ramp up in production of Pegfilgrastim and better traction in Trastuzumab. Over FY19-22, we expect earnings CAGR of 28%, led by a CAGR of 36% in Biologics and 17% in Small molecules, with a 360bp margin improvement. Further, Syngene is well positioned to move from contract research to contract manufacturing and thus Over FY19-22, we expect earnings CAGR of 20%, led by a CAGR of 36% in Biologics and 17% in Small molecules, with a 360bp margin improvement.

Syngene Internationa.. has an average target of 1030.00 from 1 broker.

Syngene International Ltd.

24 Jan 2020

698.40

2.28%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Revenues grew at ~21% CAGR in FY15-19 to | 1826 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It owns a pool...

Syngene International Ltd. has lost -21.77% in the last 6 Months

Syngene International Ltd.

26 Jul 2019

698.40

2.28%

Syngene International Ltd

Buy: Syngene International Ltd.

ICICI Securities Limited

Integrated business model, customer stickiness to the fore Revenues grew at ~21% CAGR in FY15-19 to | 1826 crore due to new client addition on a regular basis and scaled up revenues from existing clients led by integrated service offerings, high data integrity ethos and continuous endeavour to move up the value chain. Eight of the top 10 global pharma companies have been availing services for the last five years. It owns a pool...